Table 3.
Multivariable Cox regression model of overall survival in patients treated upfront with ED ICIsa
| Characteristic | Hazard ratio (95% CI) | P |
|---|---|---|
| irAEs onset | ||
| No | Referent | |
| Yes | 0.57 (0.35 to 0.93) | .02 |
| Tumor type | ||
| NSCLC | Referent | |
| Melanoma | 1.16 (0.58 to 2.33) | .66 |
| Renal | 0.51 (0.22 to 1.14) | .10 |
| Treatment setting | ||
| Adjuvant | Referent | |
| Advanced or metastatic | 7.66 (1.84 to 31.89) | .005 |
| ECOG PS | ||
| 0 | Referent | |
| ≥1 | 1.74 (1.08 to 2.79) | .02 |
a
Landmark method was used to correct for immortal time bias (all patients who died before 3 months were excluded from the analysis). CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group Performance Score; ED = extended interval dosing; ICIs = immune checkpoint inhibitors; irAEs = immune-related adverse events; NSCLC = non-small cell lung cancer.